Dover, Delaware-based Wildcat DX, LLC announced on December 6 that it acquired a 100% stake in Navis Clinical Laboratories.
Navis Clinical Laboratories, headquartered in Franklin, Tennessee, provides laboratory testing solutions tailored for healthcare providers who treat patients with substance use disorder, chronic pain, mental health conditions and other chronic health conditions. The company was founded in 2023.
Wildcat DX has a large portfolio of healthcare companies, which include: Encore Wound Care, one of the largest mobile wound care practices in the country, servicing long term care facilities across several states; Encore Surgical Supplies which is a post operative surgical dressing company; MedArbor Diagnostics, a clinical molecular laboratory that serves a full line of molecular based infectious diseases testing including urinary tract infection, respiratory, wound, women’s health and gastrointestinal panels; and Novo Health Care Services which is a technology and billing company that has developed several software platforms that include Novo LIMs, Encore Wound Tracker and Novo Rx.
As part of this transition, Dr. Damon Borg has been appointed as interim CEO. The combined healthcare entities are to exceed $200 million in yearly revenue, with 100% year over year growth. The financial terms were not disclosed.
According to data in the LevinPro HC database, this transaction marks the 110th Laboratories, MRI and Dialysis acquisition of 2024, and the 59th in the diagnostic specialty. Throughout all of 2023, there were 63 diagnostic transactions.
